Streetbeat News

Price Targets

IRTC

Needham analyst David Saxon has maintained a 'Buy' rating on iRhythm Technologies (NASDAQ:IRTC), but lowered the price target from $151 to $130.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 3:01 pm

BCYC

HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a 'Buy' rating on Bicycle Therapeutics (NASDAQ:BCYC) and maintained a price target of $57.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 3:00 pm

ATEC

Needham analyst David Saxon maintains a 'Buy' rating on Alphatec Holdings (NASDAQ:ATEC) and raises the price target from $19 to $20.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 3:00 pm

BLCO

HC Wainwright & Co. analyst Yi Chen has reiterated a 'Buy' rating on Bausch & Lomb (NYSE:BLCO) and maintained a price target of $22.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 3:00 pm

ALEC

HC Wainwright & Co. analyst Andrew Fein has reiterated a 'Buy' rating on Alector (NASDAQ:ALEC) and maintained a price target of $41.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 3:00 pm

ABUS

HC Wainwright & Co. analyst Ed Arce has reiterated a 'Buy' rating on Arbutus Biopharma (NASDAQ:ABUS), maintaining a price target of $6.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 3:00 pm

NXTC

Needham analyst Gil Blum has reiterated a 'Buy' rating on NextCure (NASDAQ:NXTC) and maintained a price target of $6.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 3:00 pm

CLFD

Needham analyst Ryan Koontz has reiterated a 'Buy' rating on Clearfield (NASDAQ:CLFD) and maintained a price target of $60.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 3:00 pm

STKS

Stephens & Co. analyst Joshua Long has reiterated an Overweight rating on The One Group Hospitality (NASDAQ:STKS) and maintained a $12 price target.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 3:00 pm

WVE

HC Wainwright & Co. analyst Andrew Fein has reiterated a 'Buy' rating on WAVE Life Sciences (NASDAQ:WVE) and maintained an $8 price target.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 3:00 pm